Tetrandrine, a
bisbenzylisoquinoline alkaloid component of broadly used
traditional Chinese medicine, has antitumor effects against some
cancers. In our study, we investigated the effects of
tetrandrine on the human
hepatocellular carcinoma (HCC) in vitro and in vivo. The results showed that
tetrandrine effectively induced apoptosis of
liver cancer cell in a dose- and time-dependent manner accompanied by alteration of cell morphology,
chromatin fragmentation and
caspase activation.
Tetrandrine treatment also induced intracellular accumulation of
reactive oxygen species (ROS), and ROS scavengers (LNAC and GSH) completely blocked the effects of
tetrandrine-induced apoptosis, suggesting that the generation of ROS plays an important role in
tetrandrine-induced apoptosis. Although the activities of JNK and ERK were inhibited significantly by
tetrandrine treatment, JNK and ERK are not involved in the
tetrandrine-induced apoptosis. In contrast, Akt activity was found to be closely related to
tetrandrine-induced apoptosis. The data demonstrated that Akt activity inhibitor
LY294002 synergistically promoted
tetrandrine-induced apoptosis of HCC, whereas ectopic expression of Akt contrastly abrogated partial of the
tetrandrine-induced apoptosis. These data suggest that Akt signal is the downstream event of ROS generation in the
tetrandrine-induced HCC cell apoptosis. Moreover, the results of xenograft in nude mice were consistent with that of the in vitro studies. Therefore, our data suggest that
tetrandrine may be a promising agent for the treatment of HCC as a regulator of ROS/Akt pathway.